CA2477328A1 - Pyridyl tricyclic compounds as farnesyl protein transferase inhibitors and antitumor agents - Google Patents

Pyridyl tricyclic compounds as farnesyl protein transferase inhibitors and antitumor agents Download PDF

Info

Publication number
CA2477328A1
CA2477328A1 CA002477328A CA2477328A CA2477328A1 CA 2477328 A1 CA2477328 A1 CA 2477328A1 CA 002477328 A CA002477328 A CA 002477328A CA 2477328 A CA2477328 A CA 2477328A CA 2477328 A1 CA2477328 A1 CA 2477328A1
Authority
CA
Canada
Prior art keywords
group
substituted
alkyl
compound
substituents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002477328A
Other languages
English (en)
French (fr)
Inventor
Hugh Y. Zhu
F. George Njoroge
Alan B. Cooper
Timothy J. Guzi
Dinanath F. Rane
Keith P. Minor
Ronald J. Doll
Viyyoor Moopil Girijavallabhan
Bama Santhanam
Patrick A. Pinto
Bancha Vibulbhan
Kartik M. Keertikar
Carmen S. Alvarez
John J. Baldwin
Ge Li
Chia-Yu Huang
Ray A. James
W. Robert Bishop
James J-S Wang
Jagdish A. Desai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Pharmacopeia LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/085,896 external-priority patent/US20030229099A1/en
Application filed by Individual filed Critical Individual
Publication of CA2477328A1 publication Critical patent/CA2477328A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/06Ring systems of three rings
    • C07D221/16Ring systems of three rings containing carbocyclic rings other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002477328A 2002-02-27 2003-02-25 Pyridyl tricyclic compounds as farnesyl protein transferase inhibitors and antitumor agents Abandoned CA2477328A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/085,896 2002-02-27
US10/085,896 US20030229099A1 (en) 2000-08-30 2002-02-27 Novel farnesyl protein transferase inhibitors as antitumor agents
US10/325,896 2002-12-19
US10/325,896 US7342016B2 (en) 2000-08-30 2002-12-19 Farnesyl protein transferase inhibitors as antitumor agents
PCT/US2003/005479 WO2003072549A1 (en) 2002-02-27 2003-02-25 Farnesyl protein transferase inhibitors as antitumor agents

Publications (1)

Publication Number Publication Date
CA2477328A1 true CA2477328A1 (en) 2003-09-04

Family

ID=27767345

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002477328A Abandoned CA2477328A1 (en) 2002-02-27 2003-02-25 Pyridyl tricyclic compounds as farnesyl protein transferase inhibitors and antitumor agents

Country Status (19)

Country Link
US (1) US7342016B2 (https=)
EP (1) EP1492772A1 (https=)
JP (1) JP2005525356A (https=)
KR (1) KR20040098004A (https=)
CN (1) CN100537542C (https=)
AR (1) AR039557A1 (https=)
AU (1) AU2003215389B2 (https=)
BR (1) BR0308071A (https=)
CA (1) CA2477328A1 (https=)
CO (1) CO5611194A2 (https=)
IL (1) IL163673A0 (https=)
MX (1) MXPA04008303A (https=)
NO (1) NO20044053L (https=)
NZ (1) NZ534809A (https=)
PE (1) PE20031038A1 (https=)
PL (1) PL372335A1 (https=)
RU (1) RU2004128465A (https=)
TW (1) TW200303867A (https=)
WO (1) WO2003072549A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05012723A (es) * 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
ES2317047T3 (es) * 2003-08-07 2009-04-16 Schering Corporation Nuevos inhibidores de la farnesil proteina transferasa como agentes antitumorales.
AU2005249494A1 (en) * 2004-05-28 2005-12-15 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
CA2569887A1 (en) 2004-06-09 2005-12-22 Glaxo Group Limited Pyrrolopyridine derivatives
CA2591123A1 (en) 2004-12-14 2006-06-22 Schering Corporation Farnesyl protein transferase inhibitors and methods for treating proliferative diseases
MX2007007611A (es) * 2004-12-21 2007-09-04 Schering Corp Nuevos inhibidores de la farnesil protein-transferasa como agentes antitumorales.
CA2637572A1 (en) * 2006-01-19 2007-07-26 Schering Corporation Piperazine derivatives as farnesyl protein transferase inhibitors
US20080090242A1 (en) * 2006-09-29 2008-04-17 Schering Corporation Panel of biomarkers for prediction of fti efficacy
TWI577695B (zh) * 2006-12-19 2017-04-11 建南德克公司 用於輔助及先導性輔助療法之血管內皮生長因子(vegf)-特異性拮抗劑及早期腫瘤之治療
WO2010006432A1 (en) * 2008-07-14 2010-01-21 Queen's University At Kingston Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
WO2010107739A2 (en) 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a flaviviridae family viral infection
US9227962B2 (en) 2013-03-13 2016-01-05 Boston Biomedical, Inc. Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative
US9187454B2 (en) * 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
CN105777646A (zh) * 2016-04-08 2016-07-20 西南科技大学 一种新的5-碘-2-苯基-1-甲基咪唑的制备方法
CN111454329A (zh) * 2020-04-07 2020-07-28 哈尔滨师范大学 一种具有抗癌活性的异茚哚酮桥连环九肽及其制备方法
WO2023071601A1 (zh) * 2021-10-28 2023-05-04 天津市昕晨投资发展有限公司 地氯雷他定衍生物、其制备方法及其用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826853A (en) 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US5393890A (en) 1988-06-02 1995-02-28 Ajinomoto Co., Inc. Piperidine derivatives and hypotensives containing the same
AU8854091A (en) 1990-10-10 1992-05-20 Schering Corporation Bis-benzo cyclohepta piperidylidene, piperidine and piperazine compounds, compositions and methods of use
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
US5643909A (en) 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
US5721236A (en) 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5719148A (en) 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL111235A (en) 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US6075025A (en) * 1993-10-15 2000-06-13 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
SK86198A3 (en) * 1995-12-22 1999-02-11 Schering Corp Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
CN1237176A (zh) * 1996-09-13 1999-12-01 先灵公司 用作fpt抑制剂的三环化合物
US5861395A (en) * 1996-09-13 1999-01-19 Schering Corporation Compounds useful for inhibition of farnesyl proteins transferase
AU4801197A (en) 1996-09-13 1998-04-02 Schering Corporation Tricyclic antitumor compounds being farnesyl protein transferase inhibit ors
US6071907A (en) 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
IL133389A0 (en) 1997-06-17 2001-04-30 Schering Corp Novel n-substituted urea inhibitors of farnesyl-protein transferase
CA2294347C (en) 1997-06-17 2008-01-29 Schering Corporation Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives for the inhibition of farnesyl protein transferase
PE86199A1 (es) 1997-06-17 1999-09-24 Schering Corp Sulfonamida inhibidor de la enzima farnesilo transferasa
HUP0003138A3 (en) 1997-06-17 2002-11-28 Schering Corp Benzpyrido cycloheptane compounds useful for inhibition of farnesyl protein transferase
US5925648A (en) 1997-07-29 1999-07-20 Schering Corporation Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
PL348293A1 (en) 1998-12-18 2002-05-20 Schering Corp Tricyclic farnesyl protein transferase inhibitors
TR200101754T2 (tr) 1998-12-18 2002-05-21 Schering Corporation Farnezil protein transferaz inhibitörleri
AU2292801A (en) * 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
SI1255537T1 (sl) 2000-02-04 2006-10-31 Janssen Pharmaceutica Nv Inhibitorji farnezil protein transferaze za zdravljenje raka dojk
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
AU2002346644A1 (en) * 2001-12-03 2003-06-17 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
ES2317047T3 (es) * 2003-08-07 2009-04-16 Schering Corporation Nuevos inhibidores de la farnesil proteina transferasa como agentes antitumorales.

Also Published As

Publication number Publication date
RU2004128465A (ru) 2005-09-27
AU2003215389A1 (en) 2003-09-09
JP2005525356A (ja) 2005-08-25
NO20044053L (no) 2004-11-26
AR039557A1 (es) 2005-02-23
US20040122018A1 (en) 2004-06-24
KR20040098004A (ko) 2004-11-18
PE20031038A1 (es) 2004-01-10
NZ534809A (en) 2007-12-21
CN100537542C (zh) 2009-09-09
WO2003072549A1 (en) 2003-09-04
AU2003215389B2 (en) 2007-10-18
CO5611194A2 (es) 2006-02-28
PL372335A1 (en) 2005-07-11
US7342016B2 (en) 2008-03-11
TW200303867A (en) 2003-09-16
CN1630641A (zh) 2005-06-22
EP1492772A1 (en) 2005-01-05
MXPA04008303A (es) 2005-11-23
BR0308071A (pt) 2004-12-21
IL163673A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
CA2477328A1 (en) Pyridyl tricyclic compounds as farnesyl protein transferase inhibitors and antitumor agents
AU711238B2 (en) Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
TW200948799A (en) Novel compounds that are ERK inhibitors
US20030229099A1 (en) Novel farnesyl protein transferase inhibitors as antitumor agents
WO2003047586A1 (en) Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
JP2005525356A5 (https=)
AU2001288451C1 (en) Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
EP1660477B1 (en) Novel farnesyl protein transferase inhibitors as antitumor agents
AU2001288451A1 (en) Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
CA2591123A1 (en) Farnesyl protein transferase inhibitors and methods for treating proliferative diseases
CN101317845B (zh) 一类6-芳基取代吡啶类化合物的药物用途
US5945430A (en) Aminooxyamide tricyclic inhibitors of farnesyl-protein transferase
US20060205755A1 (en) Novel farnesyl protein transferase inhibitors as antitumor agents
KR20010013944A (ko) 파네실 단백질 트랜스퍼라제의 억제에 유용한벤조(5,6)사이클로헵타(1,2-b)피리딘 유도체
HK1087122B (en) Novel farnesyl protein transferase inhibitors as antitumor agents
AU2007202115A1 (en) Tricyclic antitumor compounds being farnesyl protein transferase inhibitors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued